The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Further purification of a polypeptide demonstrating enterogastrone activity
Open accessAbstract
1. The further purification of a polypeptide having potent enterogastrone activity, without CCK—PZ effects, is described. 2. The material was inhibitory when doses of 1·0 μg/kg.hr were administered intravenously. Amino acid analyses demonstrated the absence of proline, a high content of glutamine and a preponderance of lysine over arginine. Tryptic degradation destroys the inhibitory effect of the polypeptide. Further studies must be performed before the physiological status of the polypeptide can be ascertained.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The electrophoresis of histones in polyacrylamide gel and their quantitative determination
Johns, E. W. (1967) · Biochemical Journal · doi:10.1042/bj1040078 · Cited by 270
Preparation of highly active enterogastrone
Brown, J. C., Pederson, R. A., Jorpes, E., & Mutt, V. (1969) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y69-020 · Cited by 189
Self-citation
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Self-citationKieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
GIP and GLP-1, the two incretin hormones: Similarities and differences
Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746
FEHMANN, H.-C., GÖKE, R., & GÖKE, B. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-3-390 · Cited by 528
Production and Evaluation of Antibodies for the Radioimmunoassay of Gastrin
Rehfeld, J. F., Stadil, F., & Rubin, B. (1972) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365517209081114 · Cited by 424
The New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
Schwartz, C. J., Kimberg, D. V., Sheerin, H. E., Field, M., & Said, S. I. (1974) · Journal of Clinical Investigation · doi:10.1172/jci107790 · Cited by 382
Identification and Actions of Gastric Inhibitory Polypeptide
BROWN, J. C., DRYBURGH, J. R., ROSS, S. A., & DUPRÉ, J. (1975) · Proceedings of the 1974 Laurentian Hormone Conference · doi:10.1016/b978-0-12-571131-9.50017-7 · Cited by 333
Self-citationGlucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288
“Owing to the original observation of inhibitory activities on gastric acid secretion, the peptide was named ‘gastric inhibitory polypeptide’ (GIP) and was postulated to primarily act as enterogastrone [11,12].”
BackgroundIntestinal Secretion: Stimulation by Peptides
Barbezat, G. O., & Grossman, M. I. (1971) · Science · doi:10.1126/science.174.4007.422 · Cited by 274
GIF biology and fat metabolism
Yip, R. G. C., & Wolfe, M. M. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00314-8 · Cited by 266
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
Osteoblast-Derived Cells Express Functional Glucose-Dependent Insulinotropic Peptide Receptors1
Bollag, R. J., Zhong, Q., Phillips, P., Min, L., Zhong, L., Cameron, R., Mulloy, A. L., Rasmussen, H., Qin, F., Ding, K. H., et al. (2000) · Endocrinology · doi:10.1210/endo.141.3.7366 · Cited by 265
Edholm, T., Degerblad, M., Grybäck, P., Hilsted, L., Holst, J. J., Jacobsson, H., Efendic, S., Schmidt, P. T., & Hellström, P. M. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01554.x · Cited by 164
PEDERSON, R. A., & BROWN, J. C. (1978) · Endocrinology · doi:10.1210/endo-103-2-610 · Cited by 156
Self-citationEffects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2011) · Experimental Diabetes Research · doi:10.1155/2011/279530 · Cited by 138
Gastric inhibitory polypeptide does not inhibit gastric emptying in humans
Meier, J. J., Goetze, O., Anstipp, J., Hagemann, D., Holst, J. J., Schmidt, W. E., Gallwitz, B., & Nauck, M. A. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00499.2003 · Cited by 126
Green, B., Gault, V., O'Harte, F., & Flatt, P. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043382774 · Cited by 111
The Origin and Understanding of the Incretin Concept
Rehfeld, J. F. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00387 · Cited by 102
Glucagon-like peptides 1 and 2 in health and disease: A review
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Peptides · doi:10.1016/j.peptides.2013.01.014 · Cited by 100
Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus
León, D. D. D., Crutchlow, M. F., Ham, J.-Y. N., & Stoffers, D. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.07.011 · Cited by 94
Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
Gutgesell, R. M., Nogueiras, R., Tschöp, M. H., & Müller, T. D. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01566-x · Cited by 61
“GIP was discovered in the early 1970s by John Brown and colleagues as the gastric-inhibitory polypeptide [28, 29].”
BackgroundO'Harte, F., Gray, A., & Flatt, P. (1998) · Journal of Endocrinology · doi:10.1677/joe.0.1560237 · Cited by 60
Jonik, S., Marchel, M., Grabowski, M., Opolski, G., & Mazurek, T. (2022) · Biology · doi:10.3390/biology11020288 · Cited by 33
TURNER, D. S., ETHERIDGE, L., JONES, J., MARKS, V., MELDRUM, B., BLOOM, S. R., & BROWN, J. C. (1974) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1974.tb02820.x · Cited by 25
Self-citationEffects on pancreatic Beta and other Islet cells of the glucose-dependent insulinotropic polypeptide
Khan, R., Tomas, A., & Rutter, G. A. (2020) · Peptides · doi:10.1016/j.peptides.2019.170201 · Cited by 24
Dual gut hormone receptor agonists for diabetes and obesity
Bass, J., Tschöp, M. H., & Beutler, L. R. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167952 · Cited by 21
Lee, H. Y., Ko, S.-H., Park, S., Kim, K., Kim, S.-Y., Cho, I.-J., Cho, E. J., Kim, H. C., Park, J.-H., Ryu, S. K., et al. (2024) · Clinical Hypertension · doi:10.1186/s40885-024-00279-4 · Cited by 10
“The first incretin to be extracted from gut mucosa was gastric inhibitory polypeptide [36].”
Background
Metadata
- Authors
- Brown, J. C., Mutt, V., & Pederson, R. A.
- Venue
- The Journal of Physiology
- Publisher
- Wiley
- Published
- 1970-07
- Volume
- 209
- Issue
- 1
- Pages
- 57-64
- ISSN
- 0022-3751 (ISSN-L)
- 1469-7793
- OpenAlex
- W2102977341
- Cited by
- 276
- References
- 2
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.